Method for cleavage of solid phase-bound peptides from the solid phase

Patent metadata

Field	Value
Publication number	US-11560402-B2
Application number	US-201916380316-A
Country	US
Kind code	B2
Filing date	Apr 10, 2019
Priority date	Apr 10, 2018
Publication date	Jan 24, 2023
Grant date	Jan 24, 2023

Abstract

The invention relates to a method for the cleavage of a solid phase-bound polypeptide from the solid phase, the method comprising contacting the solid phase, to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol, at a temperature in the range of about 23° C. to about 29° C.

First claim

The invention claimed is:

1. A method for cleavage of a solid phase-bound polypeptide from a solid phase, the method comprising contacting the solid phase to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol,
wherein percentages of the trifluoroacetic acid and the 1,2-ethanedithiol in the composition are 100% together, including impurities, which may be present in the trifluoroacetic acid and 1,2-ethanedithiol,
wherein a reaction is at a temperature of 25° C. to 27° C., and
wherein the polypeptide is selected from GLP-1, analogs and derivatives thereof, exendin-3, analogs and derivatives thereof, and exendin-4, analogs and derivatives thereof.

2. The method of claim 1 , wherein the solid phase comprises a Rink amide resin.

3. The method of claim 2 , wherein the polypeptide is bound to the Rink amide resin by a linker.

4. The method of claim 1 , wherein the composition comprises trifluoroacetic acid in an amount of 95 to 99% v/v, and 1,2-ethanedithiol in an amount of 1 to 5% v/v.

5. The method of claim 1 , wherein the composition consists essentially of trifluoroacetic acid in an amount of 97% v/v, and 1,2-ethanedithiol in an amount of 3% v/v.

6. The method of claim 1 , wherein the solid phase to which the polypeptide is bound is contacted with the composition at a temperature of 26° C. to 27° C.

7. The method of claim 6 , wherein the solid phase to which the polypeptide is bound is contacted with the composition at a temperature of 26° C.

8. The method of claim 1 , wherein the solid phase to which the polypeptide is bound is contacted with the composition for 1 to 8 h.

9. The method of claim 8 , wherein the solid phase to which the polypeptide is bound is contacted with the composition for 3 to 5 h.

10. The method of claim 1 , wherein the polypeptide is selected from exendin-4, lixisenatide, albiglutide, dulaglutide and semaglutide.

11. The method of claim 1 , wherein the cleavage of the solid phase-bound polypeptide is a step in a method of a solid-phase synthesis of the polypeptide.

12. A method for the solid-phase synthesis of a polypeptide comprising a pre-determined amino acid sequence, said method comprising:
(a) coupling an amino acid building block comprising an unprotected C-terminal carboxyl group and a protected N-terminal amino group, C-terminally to a solid phase,
(b) de-protecting the N-terminal amino group of the amino acid building block,
(c) coupling an amino acid building block, comprising an unprotected C-terminal carboxyl group and a protected N-terminal amino group, C-terminally to the unprotected N-terminal amino of step (b),
(d) optionally repeating steps (b) and (c), and
(e) cleaving the polypeptide from the solid phase by contacting the solid phase to which the polypeptide is bound with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol at a temperature of 25° C. to 27° C.,
wherein percentages of the trifluoroacetic acid and the 1,2-ethanedithiol in the composition are 100% together, including impurities which may be present in the trifluoroacetic acid and 1,2-ethanedithiol, and
wherein the polypeptide is selected from GLP-1, analogs and derivatives thereof, exendin-3, analogs and derivatives thereof, and exendin-4, analogs and derivatives thereof.

13. The method of claim 12 , wherein the polypeptide is selected from exendin-4, lixisenatide, albiglutide, dulaglutide and semaglutide.

14. The method of claim 12 , wherein the solid phase is a Rink amide resin.

15. A method for cleavage of a solid phase-bound polypeptide from a solid phase, the method comprising contacting the solid phase to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid in an amount of 97% v/v and 1,2-ethanedithiol in an amount of 3% v/v,
wherein percentages of the trifluoroacetic acid and the 1,2-ethanedithiol in the composition are 100% together, including impurities which may be present in the trifluoroacetic acid and 1,2-ethanedithiol,
wherein a reaction temperature is above room temperature, and
wherein the polypeptide is selected from GLP-1, analogs and derivatives thereof, exendin-3, analogs and derivatives thereof, and exendin-4, analogs and derivatives thereof.

Assignees

• Sanofi Aventis Deutschland

Inventors

• Fiedler Wolfgang
• Pleuss Norbert
• Henkel Bernd
• Gerken Manfred

Classifications

• C07K1/122 Primary

  Hydrolysis with acids different from HF · CPC title

• C07K14/605

  Glucagons · CPC title

• C07K1/042

  characterised by the nature of the carrier · CPC title

• C07K1/10

  using coupling agents {(C07K1/006 takes precedence)} · CPC title

• C07K1/061

  using protecting groups · CPC title